Similar articles

• Crisaborole, Dupilumab, and Sarilumab.

  Hussar DA, Lee YF. Hussar DA, et al. J Am Pharm Assoc (2003). 2017 Sep-Oct;57(5):640-643. doi: 10.1016/j.japh.2017.08.001. J Am Pharm Assoc (2003). 2017. PMID: 28882252 Review. No abstract available.
• Tralokinumab as an Alternative to Dupilumab in a Patient with Atopic Dermatitis and Asthma who Developed Hypereosinophilia: A Case Report.

  Trave I, Salvi I, Bagnasco D, Parodi A, Cozzani E. Trave I, et al. Acta Derm Venereol. 2024 Sep 19;104:adv40800. doi: 10.2340/actadv.v104.40800. Acta Derm Venereol. 2024. PMID: 39295583 Free PMC article. No abstract available.
• Dupilumab-associated lymphoproliferative disorders: a comprehensive review on clinicohistopathologic features and underlying mechanisms.

  Li M, Zhao W, Lai P, Xiao Y, Wang Y. Li M, et al. Curr Opin Immunol. 2025 Jun;94:102563. doi: 10.1016/j.coi.2025.102563. Epub 2025 May 10. Curr Opin Immunol. 2025. PMID: 40349527 Review.
• EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.

  Bakker DS, Ariens LFM, Giovannone B, Hijnen D, Delemarre EM, Knol E, Nierkens S, de Bruin-Weller MS, Thijs JL, Drylewicz J. Bakker DS, et al. Allergy. 2020 Dec;75(12):3287-3289. doi: 10.1111/all.14492. Epub 2020 Jul 24. Allergy. 2020. PMID: 33305359 Free PMC article. No abstract available.
• Dupilumab-related Granulomatous Dermatitis.

  Omer M, Khadra SB, DiMarco C. Omer M, et al. R I Med J (2013). 2024 Oct 1;107(10):7-9. R I Med J (2013). 2024. PMID: 39331004 No abstract available.